Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Stereotactic Body Radiation Therapy and ZADAXIN's® (Thymalfasin) Induced Tumor Effects in Patients With Heavily Pretreated, Metastatic Esophageal Cancer

NCT02545751 is registered in ClinicalTrials.gov with Hangzhou Cancer Hospital as lead sponsor.

NCT NCT02545751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02545751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Stereotactic Body Radiation Therapy and ZADAXIN's® (Thymalfasin) Induced Tumor Effects in Patients With Heavily Pretreated, Metastatic Esophageal Cancer
Lead sponsor
Hangzhou Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2016
Completion date
December 31, 2018
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, metastatic esophageal cancer, stereotactic body radiation therapy, thymalfasin